leadf
logo-loader
viewANGLE PLC

ANGLE announces new share placing in £12mln fundraise

The AIM-listed medial diagnostics company said it would issue new ordinary shares at a placing price of 50p each, an 8.7% discount on the last close price of 54.8p

Pound coins
The placing will open with immediate effect

ANGLE PLC (LON:AGL) has announced a conditional placing of new ordinary shares to raise proceeds of £12mln to fund a strengthening of position in the liquid biopsy market.

The AIM-listed medial diagnostics company said it would issue a total of 23,970,000 new ordinary shares at a placing price of 50p each, an 8.7% discount on the last close price of 54.8p.

READ: Liquid biopsies: The breakthrough cancer tests which AIM-listed ANGLE is already developing

The firm added that the placing was being conducted by an accelerated bookbuild process which would open with immediate effect.

ANGLE said the proceeds from the fundraising would be used with its existing cash balance to progress FDA studies, clearance and metastatic breast cancer applications, progress work on the ovarian cancer pelvic mass triage application, progress development of prostate cancer applications, undertake certain incremental product development improvements, and cover ongoing operating expenses.

Andrew Newland, ANGLE chief executive and founder, said: "The new funding will allow us to strengthen our leadership position in the emerging multi-billion dollar liquid biopsy market. The additional funding will strengthen the business in discussions with corporate partners, extend the cash runway significantly past the expected timescale for FDA clearance and will enable us to prepare for revenue growth.”

Quick facts: ANGLE PLC

Price: 53 GBX

AIM:AGL
Market: AIM
Market Cap: £91.58 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18

2 min read